# Dry Eye and the Role of Cannabinoid Receptors in Tear Production > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-receptors-dry-eye-tear-production/ > **Published:** 2021-07-20T15:31:13-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:17:02-04:00 > **Clinical Summary:** Explore how cannabinoid receptors dry eye symptoms relate to THC's impact on tear production and eye health through the endocannabinoid system. --- ### THC Regulates Tearing via Cannabinoid CB1 Receptors In Summary: Over the past decade, changes in the [legal status](https://cedclinic.com/judge-temporarily-halts-thc-ban-texas/) of cannabis in many US states have been accompanied by increasing [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/); however, the effects of its consumption on eye health are poorly documented and studied. Cannabis users, however, commonly report to experience aqueous deficiency dry eye (ADDE), a condition that can lead to blurry vision, eye pain, light sensitivity, itchy eyes, and red eyes. A pioneering study recently demonstrated the presence of [CB1 receptors](https://cedclinic.com/cb1-receptor-modulation-mira-55-no-cns-side-effects/) in axons (or nerve fibers) that innervate the eye’s lacrimal gland, which secrets the aqueous portion of the tear film. [Cannabinoid receptors](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/), including CB1 and CB2, when activated by active components of cannabis – most noticeably tetrahydrocannabinol (THC) – are responsible for the euphoric sensations that users feel. More importantly, activation of [CB1 receptors](https://cedclinic.com/cb1-receptor-modulation-mira-55-no-cns-side-effects/) by THC was shown to reduce tearing in male mice but not in female mice. Another notable observation was that the amount of CB1 receptors is approximately four- to fivefold higher in male than female mice. Based on these data, the researchers proposed that the mechanism underlying the dry eye symptoms frequently reported by cannabis users is likely THC activation of CB1 [cannabinoid receptors](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/) in the lacrimal gland. They also postulated that THC’s more ambiguous impacts in females likely result from its interactions with other unknown receptors. Through this study, the scientists not only shed light on an unknown pathway regulating tear production but also strive to explore potential molecular targets for treating ADDE. The resulting therapy would benefit patients with or without [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) alike. [More access here](https://cedclinic.com/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [The endocannabinoid receptor CB2 is a regulator of trauma-inducing anxiety and a potential target for PTSD drugs](https://cedclinic.com/cannabinoid-cb2-receptors-anxiety-ptsd-regulation/) Learn about the CB2 receptor's role in anxiety regulation and its potential as a therapeutic target for PTSD, expanding understanding of cannabinoid receptors. [Read More](https://cedclinic.com/cannabinoid-cb2-receptors-anxiety-ptsd-regulation/) [Endocannabinoid System in Mental Health Treatment Research](https://cedclinic.com/endocannabinoid-system-mental-health-research/) Explore research on the endocannabinoid system's involvement in [mental health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/) treatments, highlighting the broader impact of cannabinoid receptors. [Explore Research](https://cedclinic.com/endocannabinoid-system-mental-health-research/) [Activation of a cannabinoid receptor represents a promising therapeutic strategy for Parkinson's Disease](https://cedclinic.com/cb2-receptor-agonist-parkinsons/) Discover how cannabinoid receptor activation is being studied as a potential therapy for Parkinson's Disease, illustrating therapeutic possibilities. [Learn More](https://cedclinic.com/cb2-receptor-agonist-parkinsons/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Dry%20Eye%20and%20the%20Role%20of%20Cannabinoid%20Receptors%20in%20Tear%20Production&url=https%3A%2F%2Fcedclinic.com%2Fcannabinoid-receptors-dry-eye-tear-production%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabinoid-receptors-dry-eye-tear-production%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Dry%20Eye%20and%20the%20Role%20of%20Cannabinoid%20Receptors%20in%20Tear%20Production%20https%3A%2F%2Fcedclinic.com%2Fcannabinoid-receptors-dry-eye-tear-production%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).